이상지질혈증 시장(-2032년) : 주요 시장별 - 시장 규모, 동향, 약물 예측(역학, 질병 관리, 경쟁 평가, 미충족 수요, 임상시험 전략, 파이프라인 분석)

Dyslipidemia by Major Markets - Size, Trends and Drug Forecast including Epidemiology, Disease Management, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Pipeline Analysis to 2032

US $ 14,995 ￦ 21,172,000

Zip (Single User License)

ZIP파일 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 29,990 ￦ 42,345,000

Zip (Site License)

ZIP파일 보고서를 동일 기업의 한 부서에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 44,985 ￦ 63,518,000

Zip (Global License)

ZIP파일 보고서를 동일 기업(해외)의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

이상지질혈증 시장의 의약품 매출은 2022년부터 2032년까지 크게 성장할 것으로 예상되며, 전체 연평균 성장률(CAGR)은 10.8%에 이를 전망입니다. 2022년 전체 이상지질혈증 시장 규모는 주요 7개국에서 55억 6,000만 달러로 추산됩니다. 2022년에는미국이 41억 2,000만 달러(74%)로 세계 총 매출의 대부분을 차지했고, EU 5개국은 11억 8,000만 달러로 추정되며 세계 이상지질혈증 시장 매출의 21%, 일본의 이상지질혈증 시장 매출은 2022년 2억 5,290만 달러로 추정되며 시장의 5%를 차지했습니다.

예측 기간이 끝나는 2032년에는 155억3,000만 달러에 달할 것으로 예상되며, 미국은 세계 시장의 78%를 차지하며 시장 규모는 120억 6,000만 달러에 달할 것으로 예상됩니다. 이는 미국의 높은 이상지질혈증 유병률과 EU 5개국 및 일본에 비해 전반적으로 높은 의약품 가격 때문인 것으로 분석됩니다. 또한, 미국에서는 예측 기간 동안 이상지질혈증 시장에 진입하는 파이프라인 의약품물의 수가 EU 및 일본에 비해 많으며, EU 국가는 CAGR 8.3%로 성장하여 매출액이 26억 3,000만 달러에 달할 것으로 예상됩니다. 일본은 전체 매출의 5%를 차지하며 예측 기간 동안 12.8%의 CAGR을 나타낼 것으로 예상됩니다.

이상지질혈증 파이프라인 중 PCSK9 계열의 성장은 현재 이상지질혈증 시장에서 생물학적 제제가 확대되고 있음을 보여줍니다. 그러나 높은 가격으로 인해 규제 당국의 승인에 따라 치료를 받을 수 있는 환자와 치료를 받는 환자 사이에는 큰 격차가 있습니다. 이에 반해, 보다 일반적인 이상지질혈증 시장을 타겟으로 하는 보다 비용 효율적인 치료제는 충분한 기회를 가지고 있습니다. 머크 최초의 경구용 PCSK9 억제제 MK-0616과 같은 파이프라인 의약품물이 이러한 미충족 수요를 충족시킬 수 있을 것입니다.

이 보고서는 이상지질혈증(Dyslipidemia) 시장을 조사했으며, 2032년까지 역학 동향, 미충족 수요, 임상시험 전략, 파이프라인 분석, 경쟁 구도 등의 정보를 제공합니다.

목차

제1장 이상지질혈증 : 주요 요약

제2장 서론

제3장 질병 개요

• 병인학과 병태생리학

제4장 역학

• 질병의 배경
• 위험 요인과 병존 질환
• 세계 및 과거 동향
• 예측 조사 방법
• 이상지질혈증 역학 예측(2022년-2032년)
• 논의

제5장 질병 관리

• 진단과 치료 개요
• 질병 관리에 관한 KOL 인사이트

제6장 경쟁력 평가

• 개요

제7장 미충족 요구와 기회 평가

• 개요
• 리포 단백질을 표적으로 하는 치료법
• 효과적인 중성 지방 저하 요법
• 이상지질혈증에 대한 비용 효율이 높은 치료법
• 맞춤형 치료
• 진단, 환자 교육, 장기적인 컴플라이언스 개선

제8장 연구개발 전략

• 개요
• 임상시험 설계

제9장 파이프라인 평가

• 개요
• 임상 개발 중인 유망 약제

제10장 파이프라인 평가 분석

• 개요
• 경쟁력 평가

제11장 현재 및 향후의 시장 진출기업

• 개요
• 거래 성립 동향

제12장 시장 전망

• 세계 시장
• 미국
• EU 5개국
• 일본

제13장 부록

LSH

영문 목차

영문목차

Abstract

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the dyslipidemia market through 2032.

Examples of key findings from this report include the following -

• 2022 base year sales within the dyslipidemia market are approximately $5.6 billion across the 7MM detailed in this report. GlobalData estimates that this market will grow at a compound annual growth rate (CAGR) of 10.8% to reach $15.5 billion by the end of the forecast period.
• The growth of the PCSK9 class, among others in the dyslipidemia pipeline, highlights the current expansion of biologics into the dyslipidemia market. However, due to their high prices, there is a significant disconnect between patients who are eligible for treatment based on regulatory approval and those who receive treatment. In response to this, there is ample opportunity for more cost-effective therapies targeting the more general dyslipidemia market. This is where pipeline drugs such as Merck's first oral PCSK9 inhibitor, MK-0616, will address this unmet need.

Key Highlights

According to GlobalData, the drug sales in the dyslipidemia market are expected to grow significantly between 2022 and 2032, with an overall compound annual growth rate (CAGR) of 10.8%. In 2022, GlobalData estimated the total dyslipidemia market to be valued at $5.56 billion across the 7MM. In 2022, the US made up the majority of total global sales, with $4.12 billion (74%). The 5EU accounted for 21% of the global dyslipidemia market sales with an estimated value of $1.18 billion million and Japan's dyslipidemia market sales were estimated to be $252.9 million in 2022, accounting for 5% of the market.

By the end of the forecast period in 2032, GlobalData expects the dyslipidemia market to grow at a CAGR of 10.8%, reaching sales of $15.53 billion, with the US accounting for 78% of the global market with a market value of $12.06 billion. This could be due to the large prevalence of dyslipidemia in the US, as well as the higher overall price of drugs as compared to the 5EU and Japan. Moreover, the US has more pipeline drugs entering the dyslipidemia market during the forecast period compared to the 5EU and Japan. The 5EU is anticipated to grow with a CAGR of 8.3%, reaching sales of $2.63 billion. Japan accounts for 5% of the total sales with a CAGR of 12.8% by the end of the forecast period.

Major drivers of the dyslipidemia market growth during the forecast period are -

• The increasing global prevalence of dyslipidemia due to an increase in obesity, sedentary lifestyles, and unhealthy dietary habits. As the global population continues to age, the prevalence of dyslipidemia is likely to increase.
• Improved awareness about the health risks associated with dyslipidemia and increased efforts in screening and diagnosis are expected to lead to more people being diagnosed with the condition.
• Therapies with new targets will enter the market, which will significantly boost market growth.
• The launch of the first oral PCSK9 inhibitor, Merck's MK-0616, as well as other promising pipeline therapies, including NewAmsterdam's oral CETP inhibitor, obicetrapib, and Akcea Therapeutics's apoC-III, olezarsen.

Major barriers that will restrict the growth of the dyslipidemia market during the forecast period are:

• The price of novel launched drugs for dyslipidemia and the restriction of access to highly priced new therapies.
• Widespread use of cheap, generic drugs making it difficult for high-priced branded therapies to penetrate the market.
• Continued generic erosion of Pfizer's Lipitor, AstraZeneca's Crestor (rosuvastatin), as well as Merck's Zetia (ezetimibe) across the 7MM.

Scope

• Overview of dyslipidemia, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized dyslipidemia therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2022 to 2032.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the dyslipidemia therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for dyslipidemia treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global dyslipidemia therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM dyslipidemia therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM dyslipidemia therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Dyslipidemia: Executive Summary

• 1.1 Dyslipidemia market will exhibit strong growth during the forecast period, reaching sales of $15.53 billion in 2032
• 1.2 Key players will continue their competitive position in the dyslipidemia market over the forecast period
• 1.3 Patient compliance, the availability of cost-effective drugs, and therapies that target lipoprotein (a) are the greatest unmet needs in the dyslipidemia space
• 1.4 Late-stage pipeline therapies are anticipated to drive growth in the dyslipidemia market
• 1.5 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 Forecast methodology
• 4.5 Epidemiological forecast for dyslipidemia (2022-32)
• 4.6 Discussion

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 KOL insights on disease management

6 Competitive Assessment

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Therapies that target lipoprotein (a)
• 7.3 Efficacious triglyceride-lowering therapies
• 7.4 Cost-effective therapies for dyslipidemia
• 7.5 Personalized treatment
• 7.6 Improving diagnosis, patient education, and long-term compliance

8 R&D Strategies

• 8.1 Overview
• 8.2 Clinical trials design

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
• 12.2 US
• 12.3 5EU
• 12.4 Japan

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
• 13.4 Primary research - KOLs interviewed for this report
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
• Contact Us

관련자료